elagolix
|
|
|
- CAS-Nr.
- 834153-87-6
- Englisch Name:
- elagolix
- Synonyma:
- Elagoli;NBI 56418;(R)-4-((2-(5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-(trifluoromethyl)benzyl)-4-methyl-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)-1-phenylethyl)amino)butanoic acid;CS-2232;CS-2011;ABT-620;elagolix;Elagolix-d6;(R)-Elagolix;Elagolix
CAS
- CBNumber:
- CB51518509
- Summenformel:
- C32H30F5N3O5
- Molgewicht:
- 631.59
- MOL-Datei:
- 834153-87-6.mol
|
elagolix Eigenschaften
- Siedepunkt:
- 728.6±70.0 °C(Predicted)
- Dichte
- 1.350
- storage temp.
- Store at -20°C
- Löslichkeit
- DMSO : ≥ 100 mg/mL (158.33 mM)
- pka
- 4.40±0.10(Predicted)
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Achtung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H360 |
Kann die Fruchtbarkeit beeinträchtigen oder das Kind im Mutterleib schädigen. |
Fertility (Fruchtbarkeit) |
Kategorie 1 |
Achtung |
![GHS hazard pictograms]() src="/GHS08.jpg" width="20" height="20" /> |
|
|
| Sicherheit |
| P201 |
Vor Gebrauch besondere Anweisungen einholen. |
| P202 |
Vor Gebrauch alle Sicherheitshinweise lesen und verstehen. |
| P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
| P308+P313 |
BEI Exposition oder falls betroffen: Ärztlichen Rat einholen/ärztliche Hilfe hinzuziehen. |
| P405 |
Unter Verschluss aufbewahren. |
| P501 |
Inhalt/Behälter ... (Entsorgungsvorschriften vom Hersteller anzugeben) zuführen. |
|
elagolix Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Elagolix is a gonadotropin-releasing hormone(GnRH) receptor antagonist indicated for the management of moderate to severe pain associated with endometriosis. Elagolix is an orally administered,nonpeptide small molecule gonadotropin-releasing hormone(GnRH) receptor antagonist that inhibits endogenousGnRH signaling by binding competitively to GnRH receptors in the pituitary gland.
Elagolix results in dose-dependent suppression of luteinizing hormone(LH) and follicle-stimulating hormone(FSH) leading to decreased blood leveis of the ovarian sex hormones, estradiol and progesterone.Elagolix causes a dose-dependent decrease in bone mineral density (BMD).BMD loss is greater with increasing duration of use and may not be completely reversible after stopping treatment.
As milk production is dependent on at least minimal levels of estrogen, this product may reduce milk production.
Verwenden
Elagolix has a potential role for treating uterine bleeding associated to uterine myomas. Elagolix is also used in the methods for treatment of estrogen-dependent disorders including gonadotropin-releasing hormone (GnRH) antagonists in combination with add-back therapy.
synthetische
Elagolix was a gonadotropin-releasing hormone antagonist. It was approved in 2018 by FDA via priority review for clinical treatment of endometriosis. Based on retrosynthetic analysis, five reported synthesis routes of elagolix were summarized. They were compared and evaluated in terms of step numbers, total yields, costs, synthetic conditions and manufacturing safety. At last, the synthetic method of d6-elagolix was introduced. This review would be beneficial to the future process researches of elagolix and its deuterium analogues.
Recent Progress in the Synthesis of ElagolixDiscovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor
elagolix Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
elagolix Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 190)Lieferanten
- elagolix
- 4-[[(1R)-2-[5-(2-Fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-3,6-dihydro-4-methyl-2,6-dioxo-1(2H)-pyrimidinyl]-1-phenylethyl]amino]butanoic acid
- Butanoic acid, 4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-3,6-dihydro-4-methyl-2,6-dioxo-1(2H)-pyrimidinyl]-1-phenylethyl]amino]-
- 4-({(1R)-2-[5-(2-Fluoro-3-methoxyphenyl)-3-[2-fluoro-6-(trifluoromethyl)benzyl]-4-methyl-2,6-dioxo-3,6-dihydro-1(2H)-pyrimidinyl]-1-phenylethyl}amino)butanoic acid
- 4-[[(1R)-2-[5-(2-FLUORO-3-METHOXYPHENYL)-3-[[2-FLUORO-6-(TRIFLUOROMETHYL)PHENYL]METHYL]-4-METHYL-2,6-DIOXOPYRIMIDIN-1-YL]-1-PHENYLETHYL]AMINO]BUTANOIC ACID
- elagolix USP/EP/BP
- Seviram hydrochloride
- Elagolix (NBI-56418)
- CS-2011
- CS-2232
- Elagolix-004-R
- NBI 56418; NBI56418;NBI-56418
- (R)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-[2-fluoro-6-(trifluoromethyl)benzyl]-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyric acid
- (R)-Elagolix
- ABT-620
- Elagolix-d6
- NBI 56418
- (R)-4-((2-(5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-(trifluoromethyl)benzyl)-4-methyl-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)-1-phenylethyl)amino)butanoic acid
- Elagoli
- Elagolix Sodium Monomer
- Tropicamide Impurity 35
- Elagolix sodium
4-[[(1R)-2-[5-(2-Fluoro-3-methoxyphenyl)-3-[[2-fluoro-6- (trifluoromethyl)phenyl]methyl]-3,6-dihydro-4-methyl-2,6- dioxo-1(2H)-pyrimidinyl]-1-phenylethyl]amino]butanoic acid
- Elagolix
CAS
- 834153-87-6
- C32H30F5N3O5
- API
